Company Profile
Arvinas, Inc. Stock Price, News & Analysis
Company overview
Business overview
Arvinas is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Arvinas is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Arvinas follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Arvinas sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
ARVN is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Arvinas has a lot riding on its 2026 readouts. ARV-102, ARV-806, and ARV-393 each give the company a different angle on the degrader thesis, so the next few quarters should tell us whether that platform still has enough breadth to keep the story moving.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
Source: Arvinas, Inc.
- 02
- 03
- 04
- 05
Arvinas to Participate in Upcoming Investor Conferences
Source: Arvinas, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.